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1. Introduction 
Myocarditis is defined as myocardial inflammation allied with edema, cellular infiltration, 
apoptosis and necrosis of cardiomyocytes (Rosenstein et al., 2000). It is likely to be a 
complex disease and its etiology has been associated with various infections, systemic 
diseases, drugs, and toxins. Among them, a wide array of organisms, including viral, 
bacterial, rickettsial, fungal, and parasitic organisms have been implicated as causative 
agents (Feldman & McNamara, 2000). There are two types of myocarditis viz, lymphocytic 
and giant cell myocarditis.  
Acute myocarditis must be considered in patients who present with recent onset of cardiac 
failure or arrhythmia, though the onset of clinical cardiac symptoms may be vague in many 
patients. Fulminant myocarditis is a distinct entity characterized by the sudden onset of 
severe congestive heart failure or cardiogenic shock, usually following a flu-like illness. 
Giant cell myocarditis is a rare, frequently fatal disorder of unknown origin characterized by 
the presence of giant cell inflammatory infiltrate in the myocardium with widespread 
necrosis and degeneration of myocardial fibers (Batra & Lewis, 2001). It may be associated 
with various systemic autoimmune diseases (Kuhl & Schultheiss, 2010). 
Heart reactive autoantibodies are found in a high percentage of patients with myocarditis. 
Identified autoantigens include the ┚1 adrenoreceptor adenine dinucleotide translocator, 
branched-chain keto acid dehydrogenase, cardiac myosin, sarcolemmal and myolemmal 
proteins, connective tissue, and extracellular matrix proteins including laminin. Antigenic 
mimicry between the dominant self molecules and the infectious agents also contributes to 
the disease process (Caforio et al., 1997; Neumann et al., 1990; Maisch, 1989). 
2. Experimental autoimmune myocarditis (EAM) 
The EAM model has been extensively used as a disease model of human myocarditis 
(Kodama et al., 1990). Experimental data revealed several similarities between this model 
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and the original disease in human. The current EAM model will provide the opportunity for 
further fundamental research into myocarditis. 
EAM is similar to the giant cell myocardits and is more likely to progress into dilated 
cardiomayopathy (DCM) (Kodama et al., 1990). EAM can be induced by injection of cardiac 
myosin with Freund’s adjuvant in to the footpads of Lewis rats. The immunized rats become 
ill and immobile at day 14 and then their activity gradually recovers beginning in the fourth 
week. The diseased rats show severe myocardial damage with inflammatory cell infiltration. 
Rats with EAM that survive the acute phase develop postmyocarditis DCM after 4 months 
or more (Watanabe et al., 2001). 
Rat EAM is characterized by its high morbidity and mortality (Kamal et al., 2010). 
Pericardial effusions, cardiac enlargement and discoloration of the cardiac surface are the 
macroscopic findings of EAM (Kodama et al., 1992). These findings are common in the 
autopsy of the patients with myocarditis and EAM Lewis rats but rarely reported in other 
experimental animal models of myocarditis.  
2.1 Pathogenesis of EAM 
In the rat model of EAM, cardiac myosin is one of the major inflammation inducing agents 
used commonly. It is composed of two heavy chains of about 2000 amino acids and four 
light chains. This protein acts as antigen and stimulates the inflammatory reactions in the rat 
especially targeting the myocardium. In the rat immune system, T cells recognize 10-20 
amino acid residues, and B cells recognize 5-10 amino acid peptides as antigens. Amino acid 
residues 1539-1555 of the rat cardiac myosin ┙-chain would be the myocarditogenic epitope 
of EAM (Pummerer et al., 1996).  Direct sub fragment analysis revealed that actually several 
myocarditogenic epitopes existed on cardiac myosin.  The most effective epitope is present 
on the residues 1070-1165 of the porcine cardiac myosin ┚-chain (Inomata et al., 1995). 
Antigen-specific breakdown of self-tolerance due to the molecular mimicry of 
myocarditogenic epitopes initiates the autoimmune reaction (Jones et al., 1997). This is 
followed by the stimulation and proliferation of myocarditogenic T cells. Activated T cells 
secrete many cytokines, chemokines and other mediators, which recruit and activate other 
inflammatory cells. The inflammatory mediators damage the myocardium and interfere 
with the cardiac function (Smith & Allen, 1992; Goren et al., 1998; Ishiyama et al., 1998).  
Administration of porcine cardiac myosin with complete Freund’s adjuvant, which 
comprises of inactivated and dried Mycobacterium tuberculosis leads to antigen presentation 
of cardiac myosin-specific T cells in the peripheral lymphatic organs.  Freund’s adjuvant, an 
immunopotentiator, plays an important role in the cell-mediated immunity leads to the 
breakdown of self-tolerance by activation of antigen presenting cells, enhancement of the 
expression of major histocompatibility molecules as well as increases in vascular 
permeability.  T cells produced de novo in the bone marrow play a major role in the 
pathogenesis of the autoimmune myocarditis (Bergelson et al., 1997). Release of cardiac 
myosin from the damaged heart leads to further activation of specific T cells.  
Autoantibodies developed against the myosin bind to the injured heart and destroy them 
(Fedoseyeva et al., 2002). 
2.2 Role of inflammation in myocarditis 
Cytokines play important roles in the pathogenesis of myocarditis (Ding et al., 2010; Yuan et 
al., 2010; Huang et al., 2009; Ingkanisorn et al., 2006). Interleukin (IL) -2 mRNA appears in 
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the EAM hearts at the onset of the disease (Okura et al., 1998). Subsequently, mRNA of IL-
1┚, interferon ┛, and tumor necrosis factor (TNF) ┙ increases (Maeda et al., 2005). In the 
recovery phase IL-10 appears in the heart. IL1, IL2, IL6 and TNF┙ are involved in the 
impairment of cardiac contractility, IL1 and IL6 may induce hypertrophy of myocytes 
whereas IL1 and TNF┙ may play a role in the development of myocardial fibrosis. Th2 
cytokine IL-10 plays a protective role in the development of EAM (Watanabe et al., 2001). 
IL10 possesses immunomodulatory properties involving the inhibition of macrophage 
function and the production of proinflammatory cytokines (Nishio et al., 1999).  
In rat EAM, infiltration of the inflammatory cells into the myocardium may be mediated by 
monocyte chemoattractant protein-1 (MCP-1) or other chemokines as MCP-1 mRNA is 
strongly expressed in the heart coincident with the onset of the disease and persists until the 
recovery phase (Goser et al., 2005). Nitric oxide may also play a role in the development of 
autoimmune myocarditis, by exacerbating inflammatory responses to cardiac infections 
(Kittleson et al., 2005). 
Angiotensin (Ang) II, the principal effector peptide of the renin–angiotensin system (RAS), 
has been reported to induce immune and inflammatory response in various cardiac disease 
conditions, including atherosclerosis, hypertension, left ventricular hypertrophy, 
myocardial infarction, heart failure and myocarditis (Ferrario & Strawn, 2006; Schmieder et 
al., 2007).  
3. Renin angiotensin system (RAS) 
The RAS is a central element of the physiological and pathological responses of the 
cardiovascular system. Its primary effector hormone, Ang II, not only intercedes immediate 
physiological effects of vasoconstriction and blood pressure regulation, but is also 
implicated in inflammation, endothelial dysfunction, hypertension and heart failure (Opie & 
Sack, 2001). Many of the cellular effects of Ang II appear to be mediated by ROS generated 
by NAD(P)H oxidase (Koumallos et al., 2011). Two subtypes of Ang II receptors have been 
defined on the basis of their differential pharmacological and biochemical properties: Ang II 
type 1 receptors (AT1), which are involved in most of the well-known physiological effects 
of Ang II, and Ang II type 2 receptors (AT2), which have a less well-defined role but appear 
capable of counterbalancing some of the effects of AT1 stimulation. AT1 transactivates 
growth pathways and mediates major Ang II effects such as vasoconstriction, increased 
cardiac contractility, renal tubular sodium reabsorption, cell proliferation, vascular and 
cardiac hypertrophy, inflammatory responses, and oxidative stress. AT2 is believed to 
induce essentially opposite effects, including vasodilation, antigrowth and antihypertrophic 
effects, and to play a significant role in blood pressure (BP) regulation (Oudit & Penninger, 
2011; Horiuchi et al., 1999; Matsubara, 1998; Siragy, 2000; Carey et al., 2001). 
The discovery of Ang (1–7), an endogenous peptide which opposes the pressor, 
proliferative, profibrotic, and prothrombotic actions mediated by Ang II has contributed to 
the realization that the RAS is composed of two opposing arms: the pressor arm constituted 
by the enzyme angiotensin-converting enzyme (ACE), Ang II as the product, and the AT1 
receptor as the main protein mediating the biological actions of Ang II; the second arm is 
composed of the monocarboxypeptidase ACE2, Ang (1–7) produced through hydrolysis of 
Ang II, and the Mas receptor as the protein conveying the vasodilator, antiproliferative, 
antifibrotic, and antithrombotic effects of Ang (1–7) (Petty et al., 2009; Ferrario, 2011).  
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Hypertrophy of cardiac myocytes is an adaptive response in the damaged heart. Initially, 
hypertrophy acts as a compensatory mechanism to preserve cardiac function, but when 
sustained, it becomes a major risk factor for congestive heart failure and sudden cardiac 
death. Until recently, most in vitro and in vivo studies of the roles of AT1 and AT2 indicated 
that AT1 mediates the growth promoting, fibrotic, and hypertrophic effects of Ang II on 
cardiovascular tissues and that AT2 exerts counterbalancing suppressant effects (Gao & 
Zucker, 2011). Evidence has been provided that the circulating and local RAS promote the 
development of myocardial fibrosis in hypertensive heart disease and chronic heart failure 
where both Ang II and aldosterone stimulate collagen synthesis in a dose-dependent 
manner while Ang II additionally suppresses the activity of matrix metalloproteinase 1, the 
key enzyme of interstitial collagen degradation, that synergistically leads to progressive 
collagen accumulation within the myocardial interstitium (Lijnen & Petrov, 2003). Therefore, 
the physiological role of RAS on the development of myocardial fibrosis could be 
established. 
In addition to its role in the regulation of arterial pressure, Ang II is known to mediate 
effects on cell growth and apoptosis and to have pro-oxidative and proinflammatory effects. 
Apoptosis can be induced in cardiomyocytes by a variety of factors and pathways, a number 
of findings suggest that the effectors of the RAS can be critically involved in cardiomyocyte 
apoptosis (Fabris et al., 2011; Guleria et al., 2011; Yamada et al., 1996). 
Peroxisome proliferator activated receptors (PPARs), members of the superfamily of ligand 
regulated transcription factors, are expressed in the cardiovascular system and control 
diverse vascular functions by mediating appropriate changes to gene expression. PPAR┙ 
and PPAR┛ modulate the RAS by transcriptional control of renin, angiotensinogen, ACE 
and AT1 (Takeyama et al., 2000; Lansang et al., 2006). 
4. Angiotensin receptor blockers (ARBs)  
ARBs preferentially block AT1 and leave AT2 unopposed. Long-term administration of 
ARBs results in a several-fold increase in plasma Ang and thus a possible overstimulation of 
AT2. It is generally accepted that the effects of stimulation of AT2 on the cardiovascular 
system are beneficial and that no harm would result from increased activation of these 
receptors; indeed, activation of AT2 is believed to contribute to the benefits of blocking AT1 
(Levy, 2004).  
Various ARBs were screened for their role in the treatment of acute myocarditis and are 
found to have significant activity against acute myocarditis. ARBs prevent progression of 
systolic heart failure, thereby reducing cardiac morbidity and mortality (Lindholm et al., 
2002; Cohn & Tognoni, 2001). They also reduce myocardial damage during myocarditis. The 
major cardiovascular actions of Ang II have been reported to be mediated by the AT1, and 
AT1 antagonists are therapeutically effective for the treatment of patients with heart failure 
by reducing cytokines and oxidative stress through their anti-inflammatory effects. Thus, 
the blockade of AT1 is an important way to interrupt the RAS (Sukumaran et al., 2010). 
Recently, an AT1 antagonist has been shown to ameliorate EAM by the suppression of 
myocardial damage and inflammatory events in the myocardium in addition to 
hemodynamic modifications, and it has been reported to inhibit nitric oxide (NO) 
production in macrophages and IL 1 production. ARB treatment decreased myocardial 
fibrosis and its marker molecules (i.e. RNA expression of TGF-1 and collagen-III), and 
improved the survival rate and cardiac function in rats with DCM after myocarditis in a 
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dose dependent manner. Treatment with oral ARB improved both systolic and diastolic 
functions, increased neurohormonal parameter, such as plasma Ang II, and ameliorated 
myocardial remodeling and its marker molecules (Sukumaran et al., 2010, 2011a, 2011b; 
Shirai et al., 2005). 
4.1 ARB and oxidative stress 
EAM rats also suffer from various stresses including reactive oxygen species (ROS) 
mediated oxidative stress. There are several evidences for the adverse cardiac effects 
triggered by redox cycling of ROS, generated in part by an NADPH oxidase dependent 
pathway. Reports also add the role of Ang II in triggering the oxidative stress in which 
increase in the levels of NADPH oxidase subunits like gp91phox, NOX4, p22phox, p40phox, 
p47phox, p67phox, rac1 and 3-Nitrotyrosine in rat EAM. ARBs can block the myocardial 
oxidative stress in EAM evidenced by the decreased levels of these markers (Sukumaran et 
al., 2011b; Seko, 2006; Singh et al., 2008). 
4.2 ARB and hemodynamics 
Central venous pressure (CVP) and left ventricular end diastolic pressure (LVEDP) were 
significantly higher and mean blood pressure (MBP), LVP and +dP/dt were significantly 
lower in EAM rats indicating systolic and diastolic dysfunction. CVP and LVEDP were 
significantly decreased in the ARB treated EAM rats. Myocardial contractility parameters 
including intraventricular pressure change were improved in EAM rats treated with ARB. 
Echocardiographic analysis also showed the improvement of cardiac remodeling with ARB 
treatment evidenced by decreased LVDd and LVDs and increased fractional shortening and 
ejection fraction (Sukumaran et al., 2010; 2011a; 2011b; Shirai et al., 2005; Tsutsui et al., 2007). 
4.3 ARB and cardiomyocyte apoptosis 
Inappropriate apoptosis contributes to the pathogenesis of a number of cardiac diseases and 
is recognized as an important factor in cardiovascular remodeling. AT1 mediated 
cardiomyocyte apoptosis is due to the pathologic involvement of RAS where ARB can block 
the actions of Ang II on AT1 thereby preventing the cellular apoptosis in the myocardium. 
There were several reports indicating the myocardial apoptosis in the EAM rats and ARBs 
can effectively prevent it due to their action on RAS. For instance, ARB can block the 
endoplamic reticulum stress and caspase12 activation in the EAM rats thus prevents 
cardiomyocyte apoptosis (Singh et al., 2008; Tsutsui et al., 2007; Ye et al., 2010; Matsusaka et 
al., 2006) (Figure 1). 
4.4 ARB and inflammation in EAM 
AT1 antagonists are reported to suppress cytokine production and the transcription of 
cytokine genes in vitro and in vivo (Matsubara, 1998; Siragy, 2000; Carey et al., 2001). ARBs 
can decrease the expression of IFN-gamma (interferon-gamma), FasL (Fas ligand), iNOS 
(inducible nitric oxide synthase) and PFP (pore-forming protein) in myocardial tissue, 
indicating suppression of the activation of infiltrating killer lymphocytes (Seko, 2006). ARB 
administration downregulates Th1 cytokines (IFN-gamma and IL-2) while upregulating Th2 
cytokines (IL-4 and IL-10). Thus, studies of RAS antagonists in inflammatory diseases 
suggested that Ang II was involved in immune and inflammatory responses and ARBs are 
useful candidates in preventing the inflammation associated with those disorders. In our lab 
www.intechopen.com
 
Myocarditis 
 
314 
we have studied the action of ARB against EAM in rats. Out of 10 EAM rats used for 
treatment with ARB only 20% mortality was observed whereas control group showed 60% 
mortality. The disease severity was also decreased in the ARB treated group as shown by 
the less number of apoptotic cells, lesser fibrotic tissue replacement and also low level of 
inflammatory cellular infiltration when compared with the control group rats (Fig. 1).  
5. Conclusion 
ARBs, when added to conventional treatment for patients with heart failure, are associated 
with a reduction in morbidity and mortality as well as an improvement in quality of life. 
Clinical trials of ARB therapy indicate that these agents are generally well tolerated, both 
alone and in combination with other neurohormonal inhibitors (Patterson, 2003). Studies 
with ARB against EAM in rats provided several evidences for their protective role against 
the pathological alterations induced by Ang II (Figure 2). The treatment option with ARB 
against the cardiac complications involving Ang II has widened the area of cardiovascular 
research which will benefit the number of suffering population.   
 
 
 
 
 
Fig. 1. Cross-sectional cardiac tissue slices with TUNEL staining depicting myocardial 
apoptosis, Azan-Mallory staining for fibrosis (blue area) and Hematoxylin and eosin 
staining depicting interstitial edema, vacuolization and degeneration of cardiac fibers 
respectively (X200). Normal, age-matched normal rats; EAM, Immunized rats without 
treatment; ARB, Immunized rats administered with ARB. 
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Fig. 2. Schematic representation of angiotensin pathway following angiotensin production. 
Angiotensin II binding to AT1 receptors leads to maintenance of homeostasis in normal 
physiology whereas pathological stimulation involves major cardiovascular complications. 
Treatment with ARB can potentially benefit the patients with these complications acting by 
blocking the actions of angiotensin II on AT1 receptors. 
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